TipRanks
Zhejiang Taimei Medical Technology Co Ltd Class H (HK:2576)
:2576
Hong Kong Market
Want to see HK:2576 full AI Analyst Report?

Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Price & Analysis

0 Followers

2576 Stock Chart & Stats

HK$4.20
-HK$0.14(-3.49%)
At close: 4:00 PM EST
HK$4.20
-HK$0.14(-3.49%)

Bulls Say, Bears Say

Bulls Say
Strong 2025 Revenue ReboundThe sharp 2025 revenue rebound indicates materially stronger business activity and customer demand than in prior periods. If the higher revenue base can be maintained, it should improve operating leverage, support investment in the platform, and strengthen the company’s path toward sustainable profitability.
Improving Gross Margin And Narrower LossesHigher gross margin and substantially narrower losses show meaningful operational improvement, even though profitability has not been reached. Better economics per unit of revenue can create a stronger foundation for future scale, making eventual earnings improvement more achievable if expense growth remains controlled.
Conservatively Financed Balance SheetLow leverage reduces balance-sheet pressure and gives the company more flexibility to absorb ongoing losses or fund strategic growth. A sizable equity base also provides a financial cushion while operations develop, leaving greater room for management to execute without heavy debt-service constraints.
Bears Say
Business Remains Loss-makingNegative EBIT and EBITDA show that the operating model has not yet converted improved revenue and margins into sustainable earnings. Until the company reaches operating profitability, growth may continue to require external funding and management must prove that recent improvements can persist across future reporting periods.
Persistent Negative Cash GenerationRepeatedly negative operating and free cash flow is a material constraint because reported revenue improvement has not translated into internally generated cash. Continued cash burn can limit investment flexibility and raise funding needs, making a durable cash-flow turnaround essential to the company’s financial sustainability.
Negative Shareholder ReturnsPersistently negative return on equity indicates that shareholders’ capital is not yet producing positive earnings, despite the company’s low leverage. This weak capital productivity reinforces the need for sustained operational improvement and means balance-sheet strength has not yet translated into attractive business returns.

Zhejiang Taimei Medical Technology Co Ltd Class H News

2576 FAQ

What was Zhejiang Taimei Medical Technology Co Ltd Class H’s price range in the past 12 months?
Zhejiang Taimei Medical Technology Co Ltd Class H lowest stock price was HK$3.61 and its highest was HK$7.50 in the past 12 months.
    What is Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap?
    Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap is HK$2.55B.
      When is Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date?
      Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date is Mar 29, 2027 which is in 156 days.
        How were Zhejiang Taimei Medical Technology Co Ltd Class H’s earnings last quarter?
        Zhejiang Taimei Medical Technology Co Ltd Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.091 earnings per share for the quarter.
          Is Zhejiang Taimei Medical Technology Co Ltd Class H overvalued?
          According to Wall Street analysts Zhejiang Taimei Medical Technology Co Ltd Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Zhejiang Taimei Medical Technology Co Ltd Class H pay dividends?
            Zhejiang Taimei Medical Technology Co Ltd Class H does not currently pay dividends.
            What is Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate?
            Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Zhejiang Taimei Medical Technology Co Ltd Class H have?
            Zhejiang Taimei Medical Technology Co Ltd Class H has 200,592,530 shares outstanding.
              What happened to Zhejiang Taimei Medical Technology Co Ltd Class H’s price movement after its last earnings report?
              Zhejiang Taimei Medical Technology Co Ltd Class H reported an EPS of -HK$0.091 in its last earnings report. Following the earnings report the stock price went down -0.364%.
                Which hedge fund is a major shareholder of Zhejiang Taimei Medical Technology Co Ltd Class H?
                Currently, no hedge funds are holding shares in HK:2576
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Zhejiang Taimei Medical Technology Co Ltd Class H Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  1.42%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -5.91%
                  Trailing 12-Months
                  Asset Growth
                  4.12%
                  Trailing 12-Months
                  Learn more about TipRanks Smart Score

                  Company Description

                  Zhejiang Taimei Medical Technology Co Ltd Class H

                  Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

                  Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Century Sage Scientific Holdings Ltd
                  ―
                  ―
                  Aurum Pacific (China) Group Ltd.
                  ―
                  ―
                  Sinopharm Tech Holdings Limited
                  ―
                  ―
                  Popular Stocks